GSK plc GSK announced that the FDA approved the expanded use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 18 to 49 years who are at a higher risk of ...

The FDA has approved a third respiratory syncytial virus vaccine for high-risk adults aged younger than 50 years — a ...

March 13 (Reuters) - British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age ...

Arexvy will now compete for market share with Pfizer’s Abrysvo and Moderna’s mRESVIA in this expanded, high-risk adult ...

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the Arexvy vaccine.

The approval represents a win in what’s been a difficult regulatory environment of late for vaccine makers, and could boost uptake of a shot that’s posted flattening sales after an initially strong ...

GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk ...

The US regulator has cleared its Arexvy RSV shot for adults in that age group who are at increased ​risk of lower respiratory tract disease caused ​by the virus, having previously been cleared for the ...

GSK said the Food and Drug Administration expanded the approved age indication of its RSV vaccine to adults between the ages of 18 and 49 with increased risk of lower respiratory tract disease.

Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...